
Australian company, Genea Biocells, will open a facility in San Diego, California for cell and culture-media manufacturing and R&D.

Australian company, Genea Biocells, will open a facility in San Diego, California for cell and culture-media manufacturing and R&D.

The new column features Natrix’s signature macroporous hydrogel.

The US Pharmacopeial Convention hosts compliance seminar at CPhI China 2015.

The International Conference on Harmonization Steering Committee appoints Dr. Dawn Ronan as the new director of the ICH Secretariat.

Bristol-Myers Squibb builds R&D facilities in Massachusetts and San Francisco and discontinues discovery research in virology.

The 12th Annual Report and Survey of Biomanufacturing is now available.

The divestment of Nimenrix and Mencevax was to satisfy regulatory clearances when GSK gained Novartis’ vaccines business in an asset swap in March 2015.

IDT Biologika acquired Aeras' vaccine manufacturing facility, and the companies will work together on tuberculosis vaccine development.

Novasep's new antibody drug conjugate facility at its site in Le Mans, France will be commissioned in 2016.

Pharmacy associates say more education regarding the transactional requirements of DSCSA is needed.

apceth has completed a major GMP inspection for two medicinal products. The two cell and gene therapy products are now included in the company’s GMP manufacturing license according to §13 of the German Medicines Act (AMG).

BioSC Lab is the first in a line of next-generation chromatography equipment for protein purification in batch and continuous modes.

The agency clarifies its requirements for allowable excess volume and labeled vial fill size in injectables and biologics.

The decision makes Australia the first and only nation to permit automatic substitution of biosimilars.

A new framework featured in the Journal of Clinical Oncology will help physicians compare clinical trial results-and costs-of popular cancer medications.

The European Pharmacopoeia adopts six new texts and revises 31 monographs in its 152nd session.

Pharmaceutical Technology spoke with Monica Caphart, FDA, and Susan Schniepp, PDA, about the 2015 PDA/FDA Joint Regulatory Conference taking place in Washington, DC, in September.

Monoclonal antibodies can facilitate the entry of radiopharmaceuticals into cells, David Scheinberg said at BIO 2015.

The ruling will facilitate the market entry of generic versions of Copaxone, a widely prescribed drug to treat multiple sclerosis.

If adopted, open innovation, beyond outsourcing and licensing, could boost biopharm pipelines four-fold, a recent Deloitte study suggests.

The agency takes action against websites that illegally sell unapproved medications.

The International Conference on Harmonization finalizes Q&A document on APIs.

NIH provides an interim corrective action plan to correct deficiencies found in its Clinical Center Pharmaceutical Development Section.

Biomax Informatics AG and Pierre Fabre announced that they have entered into a collaboration to create an integrated antibody sequence and knowledge database.

Lonza’s planned facility will be used to develop and manufacture viral gene therapies and virally modified cell therapies

EvaluatePharma report shows continued pharma and biotech sector confidence.

GSK announces it will invest $95 million to launch a US-based non-profit research institute, Altius, to research technologies and approaches in understanding gene control.

The agency streamlines risk and mitigation information.

A new SGS Life Science Services laboratory outside Paris is designed for bio/pharmaceutical quality control testing.

BioSC Lab biochromatography system performs protein purification in batch and continuous modes.